These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 26738330)
21. Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity. Ding G; Wang J; Feng C; Jiang H; Xu J; Ding Q Oncotarget; 2016 Sep; 7(39):64309-64317. PubMed ID: 27602760 [TBL] [Abstract][Full Text] [Related]
22. A Constitutive Intrinsic Inflammatory Signaling Circuit Composed of miR-196b, Meis2, PPP3CC, and p65 Drives Prostate Cancer Castration Resistance. Jeong JH; Park SJ; Dickinson SI; Luo JL Mol Cell; 2017 Jan; 65(1):154-167. PubMed ID: 28041912 [TBL] [Abstract][Full Text] [Related]
23. MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets. Rane JK; Scaravilli M; Ylipää A; Pellacani D; Mann VM; Simms MS; Nykter M; Collins AT; Visakorpi T; Maitland NJ Eur Urol; 2015 Jan; 67(1):7-10. PubMed ID: 25234358 [TBL] [Abstract][Full Text] [Related]
24. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer. Wang D; Ding L; Wang L; Zhao Y; Sun Z; Karnes RJ; Zhang J; Huang H Oncotarget; 2015 Dec; 6(38):41045-55. PubMed ID: 26516927 [TBL] [Abstract][Full Text] [Related]
25. Dual strands of pre-miR‑150 (miR‑150‑5p and miR‑150‑3p) act as antitumor miRNAs targeting SPOCK1 in naïve and castration-resistant prostate cancer. Okato A; Arai T; Kojima S; Koshizuka K; Osako Y; Idichi T; Kurozumi A; Goto Y; Kato M; Naya Y; Ichikawa T; Seki N Int J Oncol; 2017 Jul; 51(1):245-256. PubMed ID: 28534948 [TBL] [Abstract][Full Text] [Related]
26. Microdissecting the role of microRNAs in the pathogenesis of prostate cancer. Ayub SG; Kaul D; Ayub T Cancer Genet; 2015 Jun; 208(6):289-302. PubMed ID: 26004033 [TBL] [Abstract][Full Text] [Related]
27. Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer. Zheng D; Gui B; Gray KP; Tinay I; Rafiei S; Huang Q; Sweeney CJ; Kibel AS; Jia L Oncogene; 2016 Sep; 35(36):4807-15. PubMed ID: 26876202 [TBL] [Abstract][Full Text] [Related]
28. The roles of microRNAs in the progression of castration-resistant prostate cancer. Kojima S; Goto Y; Naya Y J Hum Genet; 2017 Jan; 62(1):25-31. PubMed ID: 27278789 [TBL] [Abstract][Full Text] [Related]
30. miR-361-5p modulates metabolism and autophagy via the Sp1-mediated regulation of PKM2 in prostate cancer. Ling Z; Liu D; Zhang G; Liang Q; Xiang P; Xu Y; Han C; Tao T Oncol Rep; 2017 Sep; 38(3):1621-1628. PubMed ID: 29094170 [TBL] [Abstract][Full Text] [Related]
32. MiRNA 34a: a therapeutic target for castration-resistant prostate cancer. Chalanqui MJ; O'Doherty M; Dunne NJ; McCarthy HO Expert Opin Ther Targets; 2016 Sep; 20(9):1075-85. PubMed ID: 26942553 [TBL] [Abstract][Full Text] [Related]
33. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells. Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308 [TBL] [Abstract][Full Text] [Related]
34. Long Non-coding RNA SNHG17 Promotes Cell Proliferation and Invasion in Castration-Resistant Prostate Cancer by Targeting the miR-144/CD51 Axis. Bai M; Lei Y; Wang M; Ma J; Yang P; Mou X; Dong Y; Han S Front Genet; 2020; 11():274. PubMed ID: 32351538 [TBL] [Abstract][Full Text] [Related]
35. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer. Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197 [TBL] [Abstract][Full Text] [Related]
36. Identification of the Regulatory Targets of miR-3687 and miR-4417 in Prostate Cancer Cells Using a Proteomics Approach. Venz S; Junker H; Ultsch E; Hetke F; Krüger E; Burchardt M; Caetano-Pinto P; Roennau C Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142477 [TBL] [Abstract][Full Text] [Related]
37. MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2. Scaravilli M; Porkka KP; Brofeldt A; Annala M; Tammela TL; Jenster GW; Nykter M; Visakorpi T Prostate; 2015 Jun; 75(8):798-805. PubMed ID: 25731699 [TBL] [Abstract][Full Text] [Related]
38. Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis. Hagberg Thulin M; Nilsson ME; Thulin P; Céraline J; Ohlsson C; Damber JE; Welén K Mol Cell Endocrinol; 2016 Feb; 422():182-191. PubMed ID: 26586211 [TBL] [Abstract][Full Text] [Related]
39. Nuclear receptor profiling in prostatospheroids and castration-resistant prostate cancer. Wang Z; Wu D; Ng CF; Teoh JY; Yu S; Wang Y; Chan FL Endocr Relat Cancer; 2018 Jan; 25(1):35-50. PubMed ID: 29042395 [TBL] [Abstract][Full Text] [Related]
40. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells. Armstrong CM; Liu C; Lou W; Lombard AP; Evans CP; Gao AC Prostate; 2017 Jun; 77(9):1020-1028. PubMed ID: 28485104 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]